Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy


    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.


    loading  Loading Related Articles